Status:
RECRUITING
D-SOLVE Cohorts (Cohort a and B)
Lead Sponsor:
Hannover Medical School
Collaborating Sponsors:
Karolinska University Hospital
Karolinska Institutet
Conditions:
HDV
HDV Infection
Eligibility:
All Genders
18+ years
Brief Summary
Hepatitis D is by far the most severe form of chronic viral hepatitis, frequently leading to liver failure, hepatocellular carcinoma and death. Hepatitis D is caused by coinfection Hepatitis D is caus...
Detailed Description
The D-SOLVE consortium ("Understanding the individual host response against Hepatitis D Virus to develop a personalized approach for the management of hepatitis D"), aims for an unbiased screening of ...
Eligibility Criteria
Inclusion
- Anti-HDV positive
- ≥18 years old
- Sex: m/f/d
- Informed consent for prospective procedures
Exclusion
- Anti-HDV negative
Key Trial Info
Start Date :
February 22 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 30 2026
Estimated Enrollment :
750 Patients enrolled
Trial Details
Trial ID
NCT06160635
Start Date
February 22 2023
End Date
September 30 2026
Last Update
March 12 2025
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Hannover Medical School, Department of Gastroenterology, Hepatology, Infectious Disease and Endocrinology
Hanover, Germany, 30625
2
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (University of Milan)
Milan, Italy
3
Institutul de Boli Infectioase "Prof. Dr. Matei Bals"
Bucharest, Romania, 021105
4
Karolinska University Hospital and Karolinska Institutet
Stockholm, Sweden